Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccines in Veterinary Medicine
share announcement

Vaccines in Veterinary Medicine

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: closed (1 July 2023) | Viewed by 6937

Special Issue Editors

Prof. Dr. Jun Li

E-Mail Website
Guest Editor
Institute of Animal Science and Veterinary Medicine Shandong Academy of Agricultural Sciences, Jinan 250100, China
Interests: the etiology; diagnosis; vaccine development of swine emerging; re-emerging infectious diseases
Dr. Jianli Shi

E-Mail
Guest Editor
Institute of Animal Science and Veterinary Medicine Shandong Academy of Agricultural Sciences, Jinan 250100, China
Interests: etiology; diagnosis; vaccine development; emerging infectious diseases; re-emerging infectious diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Chen Li

E-Mail Website
Guest Editor
Institute of Animal Science and Veterinary Medicine Shandong Academy of Agricultural Sciences, Jinan 250100, China
Interests: the etiology; diagnosis; vaccine development of swine emerging; re-emerging infectious diseases

Special Issue Information

Dear Colleagues,

Many emerging and re-emerging diseases are significant global threats to animal and public health. As the most effective means of epidemic prevention and control, the development of the vaccine has attracted much attention. From traditional vaccines to genetically engineered vaccines based on DNA recombination technology such as subunit vaccines, live vector vaccines, transgenic plant vaccines, and third-generation vaccines, they play an important role in curbing the spread of animal diseases. We are pleased to invite you to share the latest progress on animal vaccines.

This Special Issue aims to systematically solicit new progress, new technology, and new achievements in various animal vaccines.

For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: vaccine-induced immunity, species-specific immunogen design and discovery, and vaccine epidemiology and economics, which will provide a reference for the comprehensive prevention of animal diseases. Criteria for acceptance of an article are innovativeness, clarity, novelty, and relevance to the journal’s scope.

We look forward to receiving your contributions.

Prof. Dr. Jun Li
Dr. Jianli Shi
Dr. Chen Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal
  • vaccine
  • vaccine-induced immunity
  • immunogen design
  • vaccine epidemiology and economics

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3375 KiB  
Article
Protective Efficacy of a Candidate Live-Attenuated Vaccine Derived from the SD-R Strain against NADC34-like Porcine Reproductive and Respiratory Syndrome Virus
by Hu Xu, Chao Li, Bangjun Gong, Wansheng Li, Zhenyang Guo, Qi Sun, Jing Zhao, Lirun Xiang, Jinhao Li, Yan-Dong Tang, Chaoliang Leng, Qian Wang, Jinmei Peng, Guohui Zhou, Huairan Liu, Tongqing An, Xuehui Cai, Zhi-Jun Tian and Hongliang Zhang
Vaccines 2023, 11(8), 1349; https://doi.org/10.3390/vaccines11081349 - 9 Aug 2023
Cited by 2 | Viewed by 1221
Abstract
NADC34-like porcine reproductive and respiratory syndrome virus (PRRSV) strains were first detected in China in 2017 and became major circulating strains in 2021. Our previous study showed that the live-attenuated vaccine candidate SD-R strain could provide broad cross-protection against different NADC30-like PRRSVs (sublineage [...] Read more.
NADC34-like porcine reproductive and respiratory syndrome virus (PRRSV) strains were first detected in China in 2017 and became major circulating strains in 2021. Our previous study showed that the live-attenuated vaccine candidate SD-R strain could provide broad cross-protection against different NADC30-like PRRSVs (sublineage 1.8). However, the protective effect of SD-R against NADC34-like PRRSV is unclear. Here, a novel NADC34-like PRRSV, LNTZJ1341-2012, was isolated from a pig farm experiencing disease in 2020. Sequence analysis revealed that LNTZJ1341-2012 belonged to PRRSV-2 sublineage 1.5, exhibited the same Nsp2 amino-acid deletion characteristics as IA/2014/NADC34, and had not recombined with other strains. Additionally, a good challenge model was established to evaluate the protection afforded by the candidate SD-R vaccine against infection with a representative NADC34-like strain (LNTZJ1341-2012). The control piglets in the challenge experiment displayed clinical signs typical of PRRSV infection, including transient fever, high viremia, mild clinical symptoms, and histopathological changes in the lungs and submaxillary lymph nodes. In contrast, SD-R vaccination significantly reduced serum and lung tissue viral loads, and vaccinated piglets did not show any clinical symptoms or histopathological changes. Our results demonstrated that LNTZJ1341-2012 is a mildly virulent NADC34-like PRRSV and that the live-attenuated vaccine SD-R can prevent the onset of clinical signs upon challenge with the NADC34-like PRRSV LNTZJ1341-2012 strain, indicating that SD-R is a promising vaccine candidate for the swine industry. Full article
(This article belongs to the Special Issue Vaccines in Veterinary Medicine)
►▼ Show Figures

Figure 1

12 pages, 23332 KiB  
Article
Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis
by Zhandos Abay, Ainur Nurpeisova, Kamshat Shorayeva, Sandugash Sadikaliyeva, Bolat Yespembetov, Nazym Syrym, Makhpal Sarmykova, Kuanysh Jekebekov, Ruslan Abitayev, Gaukhar Tokkarina, Elina Kalimolda, Zharkinay Absatova, Sabina Moldagulova, Han Sang Yoo, Markhabat Kassenov, Kunsulu Zakarya and Yergali Abduraimov
Vaccines 2023, 11(7), 1199; https://doi.org/10.3390/vaccines11071199 - 4 Jul 2023
Viewed by 1362
Abstract
This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for bovine tuberculosis, using an influenza vector with the NS1 mutation and expressing M. bovis protective antigens ESAT-6 and TB10.4. We vaccinated Balb/c outbred [...] Read more.
This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for bovine tuberculosis, using an influenza vector with the NS1 mutation and expressing M. bovis protective antigens ESAT-6 and TB10.4. We vaccinated Balb/c outbred mice two times at 21 days apart. Our experimental design includes mice immunised with the candidate vaccine with or without adjuvant 15% Montanide Gel. The candidate vaccine’s safety was determined by biometric analysis, and protective efficacy was assessed by bacteriological and histological experiments following a virulent M. bovis-8 strain challenge. Our data indicated that the adjuvant-free version of the vaccine ensured complete protection from the M. bovis-8 infection in mice. Full article
(This article belongs to the Special Issue Vaccines in Veterinary Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

31 pages, 2979 KiB  
Review
Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs
by Inés Có-Rives, Ann Ying-An Chen and Anne C. Moore
Vaccines 2023, 11(2), 450; https://doi.org/10.3390/vaccines11020450 - 16 Feb 2023
Cited by 5 | Viewed by 3893
Abstract
The advantages of skin-based vaccination include induction of strong immunity, dose-sparing, and ease of administration. Several technologies for skin-based immunisation in humans are being developed to maximise these key advantages. This route is more conventionally used in veterinary medicine. Skin-based vaccination of pigs [...] Read more.
The advantages of skin-based vaccination include induction of strong immunity, dose-sparing, and ease of administration. Several technologies for skin-based immunisation in humans are being developed to maximise these key advantages. This route is more conventionally used in veterinary medicine. Skin-based vaccination of pigs is of high relevance due to their anatomical, physiological, and immunological similarities to humans, as well as being a source of zoonotic diseases and their livestock value. We conducted a systematic mapping review, focusing on vaccine-induced immunity and safety after the skin immunisation of pigs. Veterinary vaccines, specifically anti-viral vaccines, predominated in the literature. The safe and potent skin administration to pigs of adjuvanted vaccines, particularly emulsions, are frequently documented. Multiple methods of skin immunisation exist; however, there is a lack of consistent terminology and accurate descriptions of the route and device. Antibody responses, compared to other immune correlates, are most frequently reported. There is a lack of research on the underlying mechanisms of action and breadth of responses. Nevertheless, encouraging results, both in safety and immunogenicity, were observed after skin vaccination that were often comparable to or superior the intramuscular route. Further research in this area will underlie the development of enhanced skin vaccine strategies for pigs, other animals and humans. Full article
(This article belongs to the Special Issue Vaccines in Veterinary Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop